These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 16357128

  • 1. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
    Kambara H, Saeki Y, Chiocca EA.
    Cancer Res; 2005 Dec 15; 65(24):11255-8. PubMed ID: 16357128
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.
    Clin Cancer Res; 2009 Apr 15; 15(8):2777-88. PubMed ID: 19351762
    [Abstract] [Full Text] [Related]

  • 3. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
    Kambara H, Okano H, Chiocca EA, Saeki Y.
    Cancer Res; 2005 Apr 01; 65(7):2832-9. PubMed ID: 15805284
    [Abstract] [Full Text] [Related]

  • 4. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
    Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J.
    Cancer Res; 2006 Feb 15; 66(4):2314-9. PubMed ID: 16489036
    [Abstract] [Full Text] [Related]

  • 5. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA.
    Gene Ther; 2007 Jul 15; 14(13):1045-54. PubMed ID: 17429445
    [Abstract] [Full Text] [Related]

  • 6. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y, Todo T.
    Brain Nerve; 2009 Jul 15; 61(7):815-22. PubMed ID: 19618859
    [Abstract] [Full Text] [Related]

  • 7. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
    Li H, Zeng Z, Fu X, Zhang X.
    Cancer Res; 2007 Aug 15; 67(16):7850-5. PubMed ID: 17699791
    [Abstract] [Full Text] [Related]

  • 8. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.
    Huszthy PC, Goplen D, Thorsen F, Immervoll H, Wang J, Gutermann A, Miletic H, Bjerkvig R.
    Clin Cancer Res; 2008 Mar 01; 14(5):1571-80. PubMed ID: 18316582
    [Abstract] [Full Text] [Related]

  • 9. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
    Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A.
    Mol Ther; 2006 Dec 01; 14(6):789-97. PubMed ID: 17045531
    [Abstract] [Full Text] [Related]

  • 10. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
    Wakimoto H, Johnson PR, Knipe DM, Chiocca EA.
    Gene Ther; 2003 Jun 01; 10(11):983-90. PubMed ID: 12756419
    [Abstract] [Full Text] [Related]

  • 11. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S, Guo ZS, O'Malley ME, Yin X, Zeh HJ, Bartlett DL.
    Gene Ther; 2007 Apr 01; 14(8):638-47. PubMed ID: 17268533
    [Abstract] [Full Text] [Related]

  • 12. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1546-57. PubMed ID: 17077357
    [Abstract] [Full Text] [Related]

  • 13. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y.
    Gene Ther; 2006 Apr 01; 13(8):705-14. PubMed ID: 16421599
    [Abstract] [Full Text] [Related]

  • 14. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M, Rabkin SD, Martuza RL.
    Cancer Res; 2007 Jan 15; 67(2):440-4. PubMed ID: 17234749
    [Abstract] [Full Text] [Related]

  • 15. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
    Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, Coffin RS.
    J Gene Med; 2007 Feb 15; 9(2):99-106. PubMed ID: 17256802
    [Abstract] [Full Text] [Related]

  • 16. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.
    Clin Cancer Res; 2006 Nov 15; 12(22):6791-9. PubMed ID: 17121900
    [Abstract] [Full Text] [Related]

  • 17. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
    Griffith C, Noonan S, Lou E, Shillitoe EJ.
    Cancer Gene Ther; 2007 Dec 15; 14(12):985-93. PubMed ID: 17853922
    [Abstract] [Full Text] [Related]

  • 18. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
    Kamiyama H, Zhou G, Roizman B.
    Gene Ther; 2006 Apr 15; 13(7):621-9. PubMed ID: 16292350
    [Abstract] [Full Text] [Related]

  • 19. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K, Dias JD, Bauerschmitz GJ, Hakkarainen T, Aavik E, Ranki T, Pisto T, Särkioja M, Desmond RA, Kanerva A, Hemminki A.
    Gene Ther; 2007 Jun 15; 14(11):902-11. PubMed ID: 17377596
    [Abstract] [Full Text] [Related]

  • 20. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
    Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt AJ, Szalay AA.
    Clin Cancer Res; 2012 May 01; 18(9):2579-90. PubMed ID: 22379115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.